TY - JOUR
T1 - Current advances and future perspectives in extrusion-based bioprinting
AU - Ozbolat, Ibrahim T.
AU - Hospodiuk, Monika
N1 - Funding Information:
This work has been supported by National Science Foundation CMMI Awards 1349716 and 1462232 , Diabetes in Action Research and Education Foundation grant # 426 and the Grow Iowa Values Funds through The University of Iowa . We would like to thank Ms. Laura L. Hupp, associate attorney in Shook, Hardy & Bacon L.L.P., for her insight on regulatory issues. We thank Melanie Laverman, Rebecca Barrett and Dr. Adil Akkouch from The University of Iowa for for their assistance with typesetting the article. The authors would like to express their gratitude to Dr. Christopher Barnatt (ExplainingTheFuture.com), Prof. J. Alblas (University Medical Center Utrecht), Prof. A. Khademhosseini (Harvard University), Prof. J. Hosek (Czech Technical University in Prague), Prof. W. Sun (Drexel University and Tsinghua University), Prof. J.A. Lewis (Harvard University), Prof. G.D. Prestwich (University of Utah), and Prof. M. Mc Alpine (Princeton University) in providing the high-quality images of some figures.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2016
Y1 - 2016
N2 - Extrusion-based bioprinting (EBB) is a rapidly growing technology that has made substantial progress during the last decade. It has great versatility in printing various biologics, including cells, tissues, tissue constructs, organ modules and microfluidic devices, in applications from basic research and pharmaceutics to clinics. Despite the great benefits and flexibility in printing a wide range of bioinks, including tissue spheroids, tissue strands, cell pellets, decellularized matrix components, micro-carriers and cell-laden hydrogels, the technology currently faces several limitations and challenges. These include impediments to organ fabrication, the limited resolution of printed features, the need for advanced bioprinting solutions to transition the technology bench to bedside, the necessity of new bioink development for rapid, safe and sustainable delivery of cells in a biomimetically organized microenvironment, and regulatory concerns to transform the technology into a product. This paper, presenting a first-time comprehensive review of EBB, discusses the current advancements in EBB technology and highlights future directions to transform the technology to generate viable end products for tissue engineering and regenerative medicine.
AB - Extrusion-based bioprinting (EBB) is a rapidly growing technology that has made substantial progress during the last decade. It has great versatility in printing various biologics, including cells, tissues, tissue constructs, organ modules and microfluidic devices, in applications from basic research and pharmaceutics to clinics. Despite the great benefits and flexibility in printing a wide range of bioinks, including tissue spheroids, tissue strands, cell pellets, decellularized matrix components, micro-carriers and cell-laden hydrogels, the technology currently faces several limitations and challenges. These include impediments to organ fabrication, the limited resolution of printed features, the need for advanced bioprinting solutions to transition the technology bench to bedside, the necessity of new bioink development for rapid, safe and sustainable delivery of cells in a biomimetically organized microenvironment, and regulatory concerns to transform the technology into a product. This paper, presenting a first-time comprehensive review of EBB, discusses the current advancements in EBB technology and highlights future directions to transform the technology to generate viable end products for tissue engineering and regenerative medicine.
UR - http://www.scopus.com/inward/record.url?scp=84961219034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961219034&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2015.10.076
DO - 10.1016/j.biomaterials.2015.10.076
M3 - Review article
C2 - 26561931
AN - SCOPUS:84961219034
VL - 76
SP - 321
EP - 343
JO - Biomaterials
JF - Biomaterials
SN - 0142-9612
ER -